GSK-189254

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H25N3O2
Molecular Weight	351.4421
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CNC(=O)C1=CC=C(OC2=CC=C3CCN(CCC3=C2)C4CCC4)N=C1

InChI

InChIKey=WROHEWWOCPRMIA-UHFFFAOYSA-N

InChI=1S/C21H25N3O2/c1-22-21(25)17-6-8-20(23-14-17)26-19-7-5-15-9-11-24(18-3-2-4-18)12-10-16(15)13-19/h5-8,13-14,18H,2-4,9-12H2,1H3,(H,22,25)

HIDE SMILES / InChI

Molecular Formula	C21H25N3O2
Molecular Weight	351.4421
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H3 receptor 46 Target ID: CHEMBL264 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17327487	Antagonist 2849		9.6 null [pKi]

PubMed

Title	Date	PubMed
Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.	2011-07-14	21634396
Antinociceptive effects of histamine H3 receptor antagonist in the preclinical models of pain in rats and the involvement of central noradrenergic systems.	2010-10-01	20682302
When reversible ligands do not reverse, and other modelers' dilemmas.	2010-07	20554739
Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET.	2010-07	20554726
Regional differential effects of the novel histamine H3 receptor antagonist 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats.	2010-01	19815811
11C-GSK189254: a selective radioligand for in vivo central nervous system imaging of histamine H3 receptors by PET.	2009-12	19910432
H3 receptor antagonism enhances NCAM PSA-mediated plasticity and improves memory consolidation in odor discrimination and delayed match-to-position paradigms.	2009-11	19657331
Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice.	2009-05	19413575
Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid over-expressing TASTPM mice.	2009-05	19222483
Novel histamine H3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain.	2008-08-15	18164820
Soraprazan: setting new standards in inhibition of gastric acid secretion.	2007-06	17369284
GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.	2007-06	17327487

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:39:55 GMT 2025` Edited by `admin` on `Mon Mar 31 21:39:55 GMT 2025`
Record UNII	5T4TX6CO53
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GSK-189254 FREE BASE

Preferred Name

English

GSK-189254

Code

English

6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPIN-7-YL)OXY)-N-METHYL-3-PYRIDINECARBOXAMIDE

Systematic Name

English

GSK-189254A

Common Name

English

Code System Code Type Description

SMS_ID

300000042429